AGTC XLRS Platform Well Tolerated (OIS@AAO 2016)

Описание: "Posterior Segment Company Showcase: AGTC" panel from Healthegy's OIS@AAO 2016:

Presenter:
Sue Washer, President & CEO – AGTC

Early reports of AGTC’s lead gene therapy program for X-linked retinoschisis have shown the treatment to be well-tolerated with only mild-to-moderate inflammation that either resolves spontaneously or with steroids, AGTC president and CEO Susan B. Washer told the Posterior Segment Company Showcase at OIS@AAO 2016.

The XLRS platform is already in Phase I with eight patients enrolled and seven US centers participating, she said. AGTC is partnering with Biogen on the XLRS and XLRP platforms, the latter for X-linked retinitis pigmentosa. The next phase for the XLRP program is to file the IND, Washer noted.
But AGTC wholly owns rights to four other programs it’s developing, two each in acrhomatopsia and age-related macular degeneration (AMD). The AMD programs are still in the proof-of-concept phase, but the achromatopsia programs are further along: the CNGB3 program is in a dose-escalation Phase I/II trial, whereas CNGA3 is close to IND filing, Washer said.

Continue Reading About AGTC Here:
http://ois.net/agtc-xlrs-platform-wel...

For more on Ophthalmology Innovation News & Events visit:
http://ois.net/